Jardiance filed in Japan for chronic kidney disease
Nippon Boehringer Ingelheim and Eli Lilly Japan said on January 31 that their SGLT2 inhibitor Jardiance (empagliflozin) was filed with Japanese regulatory authorities for an additional indication of chronic kidney disease (CKD)
The submission follows data from the global PIII EMPA-KIDNEY trial, which enrolled 6,609 participants diagnosed with CKD including Japanese. In the study, Jardiance on top of standard of care significantly cut the risk of CKD progression or cardiovascular death by 28% versus placebo.
Related news and insights
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.
Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at risk of recurrence.
Iovance Biotherapeutics, Inc. announced it has completed its rolling Biologics License Application (BLA) submission to the FDA for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced (unresectable or metastatic) melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting.